[Skip to Navigation]
March 1989

Apraclonidine Hydrochloride in Vitreoretinal Surgery

Arch Ophthalmol. 1989;107(3):316-317. doi:10.1001/archopht.1989.01070010326005

To the Editor.  —Topical 1% apraclonidine hydrochloride, an α-adrenergic agonist, reduces intraocular pressure in normal volunteers by approximately 40%.1 The onset of action occurs within one hour and the maximum intraocular pressure reduction usually appears three to five hours after application of a single dose. Its efficacy in decreasing acute intraocular pressure elevation following anterior segment laser surgery has been demonstrated.2 Apraclonidine has not been approved by the Food and Drug Administration for use after retinal reattachment or vitreous surgery. We report the use of apraclonidine in two patients to reduce the intraocular pressure elevation following pneumatic retinopexy and nondrainage retinal reattachment surgery.

Report of Cases. 

—Patient 1. 

Add or change institution